Payment & Shipping Terms:
|CAS:||159351-69-6||Alias:||Everolimus , RAD001|
|Apparence:||Almost White Crystalline Powder||Purity:||99.5%|
|Stock:||Enough Stock||Grade:||Pharma Grade|
Everolimus (RAD001) for Research 159351-69-6 Breast cancer Pancreatic cancer
Drug Type: Everolimus is a targeted therapy and is classified as an mTOR inhibitor.
Everolimus CAS 159351-69-6 Brand: NEWBIO
MW: 958.22 MSDS: Inavaiable
MF:C53H83NO14 Sample: Avaiable
Category: API Min order: 10grams
Quality standard: 99.50% HPLC Place of Origin:China
Appearance Everolimus is a macrolide derived from Rapamycin (sc-3504) and shown to inhibit cell proliferation induced by growth factors. Macrolides belong to a group of antibiotics that bind to the 50S ribosomal subunit and inhibit protein synthesis. Studies indicate that Everolimus is a mTOR (FRAP) inhibitor that displays high affinity toward the intracellular receptor FKBP12. Additionally, the Everolimus-FKBP12 complex decreases the activity of the S6K1 and 4EBP by binding to FRAP.
Applications Pharmaceutical raw materials An inhibitor of FRAP (mTOR)
Jusheng Packing: 1)Aluminum Foil Bag: 100g, 500g, 1Kg 2)Fiber Drum: 25Kg
Jusheng Delivery Method: HKEMS, DHL, TNT, UPS, FEDEX, EMS, China Air Post etc.
Jusheng Clearance Rate: 100% Custom Pass, Diguised Package and Safe Delivery
Jusheng Delivery Time: 5-14 Working Days, Tracking Number Available
Jusheng Payment Terms: T/T, MoneyGram, Western Union and Bitcoin
Jusheng Origin: Hubei Province, China
Jusheng Brand Name: Jusheng Brand
Jusheng Production Capacity: 1000Kg/Month
Everolimus is a Kinase Inhibitor. It’s brand name is Afinitor. Everolimus is a derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties.The mechanism of action of everolimus is as a Protein Kinase Inhibitor, and Cytochrome P450 3A4 Inhibitor, and P-Glycoprotein Inhibitor, and Cytochrome P450 2D6 Inhibitor.
In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production.
Everolimus is a biological therapy treatment for
Advanced breast cancer if you have been through the menopause (post menopausal). You take it with the hormone therapy drug exemestane
Advanced kidney cancer that has come back either during or after treatment.
Neuroendocrine tumours of the pancreas that can't be removed with surgery or have spread (metastatic disease).
Researchers are also looking at everolimus as a treatment for head and neck cancer and cancer of the food pipe (oesophageal cancer).
Everolimus approved indications
Stop using Everolimus (Afinitor) and call your doctor at once if you have:
|Doclatasvir Dihydrochloride||cas no.1009119-65-6|
|Ledipasvir Gs588||cas no.1256388-51-8|